Ruti Aga and the Six-Year Ban: One Forged Prescription That Turned a Two-Year Case Into Career Death

In September, when the Athletics Integrity Unit's investigators opened the file Ruti Aga had submitted in her defence, their eyes went first to an address. The clinic printed on the prescription did not exist. The "doctor" who wrote it was a family member with no medical registration, and when questioned he said he had used "an old prescription pad from a former workplace" — a workplace that promptly disowned the document entirely.

Three separate verifications. All three failed. A fake address, an unregistered practitioner, and a pad the clinic refused to call its own.

There is no finish-line story here. This is the story of a piece of paper that shut down a 32-year-old marathoner's career for six years — and it did so over a substance most of the reporting described incorrectly.

Ruti Aga is an Ethiopian marathoner. She won the 2026 Tokyo Marathon. She has three second-place finishes at World Marathon Majors. Her Berlin 2026 mark was roughly 2:18:34 — that figure is not in the original report, comes from external records, and remains pending verification. The primary source for this article is the AIU statement released on Thursday; nearly every other data point in the original report is unattributed, which is the first problem with it.

The sequence is straightforward. In March this year Aga won a half marathon in China. An in-competition sample taken there returned methylprednisolone. She explained it as treatment for a knee injury. The AIU opened a case, a provisional suspension took effect on 10 September, and the decision has now landed — a six-year ban, counted from the same 10 September.

No performance data exists in this case. No time for the Chinese race, no splits, no field strength. Inferring "form" from any of it would be dishonest. The only fact available is that she won the race — and there is solid reason to believe it was a World Athletics Label-tier event with AIU testing, because without testing there is no sample.

Read the arithmetic of the sanction. Two years for presence, four years for tampering. Six in total. That arithmetic is itself the news, because it tells us the panel rejected the no-significant-fault mitigation. Methylprednisolone sits in class S9 of the WADA Prohibited List — it is a glucocorticoid, not an anabolic steroid. That distinction is the hinge of the entire case, and the original report got it wrong.

S9 substances are prohibited in-competition only, and only by injection, oral or rectal routes. Which means a therapeutic knee injection administered out of competition is entirely legal. It becomes a violation only if residues are present in an in-competition sample. A road race's testing window opens at 23:59 the day before the race. The question was never the drug. It was route and timing.

Aga had a legitimate defence available to her. With genuine medical records, a documented injection date and route, and a TUE process followed, this case might never have reached even two years. Instead a prescription was manufactured. And the moment it was manufactured, the one defence that could actually have worked was destroyed. The document she treated as a shield became the blade.

This is where my 2026 experience comes back. A Delhi sports marketing firm handed me a 14-athlete sponsorship roster — long jumpers, discus throwers, one 400m hurdler — all sitting on sports-quota payrolls at ONGC, Railways and Services. I built the first standardised appearance-fee and image-rights template on that account: three payment tranches, each released only against a verified personal best or qualifying mark, plus a mandatory NADA whereabouts clause. Twelve of the fourteen signed inside one season, and two state units copied the format wholesale. The first contract template told us what the system was missing — and what is missing here is a credentialed team physician.

An athlete with no registered team doctor is an athlete without the clause that could have saved her. Chronic knee pathology is the most common load-bearing failure in high-volume marathoners. Getting an injection is ordinary sports medicine. The gap between getting the injection and getting it documented is where this career died.

Add another layer: the Chinese label-race circuit. For East African marathoners it is a fat appearance-fee, low-risk income tier between Majors. That same tier is now the AIU's highest-yield testing ground. The money economy and the testing economy are colliding in the same races. This is what the javelin tracker taught me — the tracker was never really about the javelin, it was about access to a pipeline. This case is less about methylprednisolone and more about access to paperwork.

What the statement does not clarify is the scope of disqualification. Standard AIU practice voids the result and prize money of the competition where the sample was collected, along with ranking points accrued after that date. Earlier results — including the 2026 Tokyo title — do not fall automatically absent evidence of earlier use. That distinction matters, because it tells us what the sanction is attached to: one March race, not an entire career.

An appeal route exists, typically within about 21 days of the reasoned decision at CAS. But a document-based finding is the hardest kind to overturn. When three independent verifications have failed, a lawyer has very little left to say.

One more thing worth noting: the Ethiopian federation has issued no statement at all in this matter. Only the AIU is speaking. When the system itself stays silent, what is left for the athlete? No press release answers that.

Now the part that slides too easily into sentiment.

Six years. For a substance with no proven endurance benefit. This sanction will hand ammunition to those who argue the AIU is harsher on African road runners. I will not dismiss that argument outright, and I will not leave it vague either.

Look at the arithmetic: two years for presence, four for tampering. The real cause of the sanction is not the drug, it is the paper. Had Aga stayed silent, or simply said the knee was under treatment and produced records, the worst case was two years and probably less. She bought the six herself. No panel imposed it out of nowhere.

I watched this machinery up close in 2026-11. October 2026, Krishna Poonia's 61.51m at the Jawaharlal Nehru Stadium — India's first individual Commonwealth athletics gold since Milkha Singh in 2026 — and I ran the sponsor activation around it: 40 appearances across nine days for one PSU client. Twelve months later CAS-confirmed bans fell on six women athletes, including relay members from that same Delhi cycle. Four of my campaigns were live. I killed all four within 72 hours and drafted a nine-point due-diligence protocol — testing history, supplement logs, whereabouts filings. We learned more from six bans than from one gold.

So there is no room for softness here. But one thing must be said: a system that gives an athlete no credentialed doctor, no understanding of TUEs, and no comfortable language-and-translation position during questioning carries part of its own sanction. The four tampering years go on the athlete's account. Whose account the compulsion to tamper goes on, the AIU statement does not say. And until it does, the next queue will form along the same route.

Aga is 32. She returns at 38. Ethiopia's women's marathon depth is such that a 2:18 performer is not automatically selectable — and a 38-year-old with a doping record never is. Functionally this is a lifetime ban; on paper it is six years. The 2026 Tokyo title and three Major second places stay on the record, while the March race result and its prize money are almost certainly void.

The real signal in this case is that the enforcement frontier has moved. The question used to be what was in the sample. The question now is whether the paper is real. Entourages, agents and "doctors" are next in line. Any athlete not keeping a single receipt for their treatment today is the lead subject of tomorrow's statement. We stopped guessing when the athlete data started moving — in this case the data did not move. The paper did.